Shots:

• Genmab to receive $150M as option exercise fee- $125M as development milestones and 20% royalties on sales of HexaBody-CD38 till 2031- following 13-20% in future. Genmab to fund the R&D activities till completion of clinical proof of concept studies in multiple myeloma and diffuse large B-cell lymphoma
• Janssen to get exclusive WW license option to develop & commercialize HexaBody-CD38- based on the proof of concept study results. If the option is not exercised- Genmab will get rights to develop and commercialize HexaBody-CD38 for DARZALEX-resistant patients and other indications (Ex- multiple myeloma or amyloidosis indications)
• HexaBody-CD38 is a next-generation CD38 mAb product developed using Genmab’s HexaBody technology and has shown promising pre-clinical data in multiple myeloma- lymphoma and leukemia models  

Ref: Janssen | Image: Janssen